Ascendis Pharma A (ASND) Receivables (2012 - 2026)

Ascendis Pharma A has reported Receivables for 15 years, with the latest figure at $209.2 million in Q1 2026.

• Quarterly Receivables rose 164.42% year-over-year to $209.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $209.2 million (up 164.42% YoY) and the FY2025 annual result came in at $181.5 million, down 3.32% from the prior year.
• Receivables grew to $209.2 million in Q1 2026 per ASND's latest filing, from $181.5 million in the prior quarter.
• Over five years, Receivables peaked at $209.2 million in Q1 2026 and troughed at $20.1 million in Q3 2022.
• A 5-year average of $85.1 million and a median of $59.1 million in 2023 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2025: Receivables decreased 18.09% in 2022, then surged 217.68% in 2025.
• Over 5 years, Receivables stood at $25.2 million in 2022, then jumped by 134.3% to $59.1 million in 2023, then surged by 217.38% to $187.7 million in 2024, then decreased by 3.32% to $181.5 million in 2025, then advanced by 15.26% to $209.2 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $209.2 million, $181.5 million, and $168.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.